Seagen

Seagen FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Seagen (SGEN) as of Oct 30, 2026 is 93.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 87.02 % — a change of 7.41% (higher).

FCF Conversion

93.47 %

YoY

7.41%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Seagen is 2023 93.47 % . FCF Conversion Rate (FCF/EBITDA) of Seagen was 2022 87.02 % . It decreases by 7.41% higher compared to the previous year.

The Seagen FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
89.08 USD
Jan 1, 2017
150.78 USD
Jan 1, 2018
100.93 USD
Jan 1, 2019
370.79 USD
Jan 1, 2020
126.15 USD
Jan 1, 2021
81.74 USD
Jan 1, 2022
87.02 USD
Jan 1, 2023
93.47 USD
The Seagen FCF Conversion history
YEARFCF ConversionYoY
93.47 %+7.41%
87.02 %+6.45%
81.74 %-35.20%
126.15 %-65.98%
370.79 %+267.39%
100.93 %-33.07%
150.78 %+69.27%
89.08 %-26.79%
121.67 %+20.04%
101.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seagen Stock analysis

What does Seagen do? Seagen Inc is a pharmaceutical and biotech company specialized in the development of drugs for cancer treatment and supporting the health of patients with chronic diseases. The company was founded in 1997 and has its headquarters in Bothell, Washington. Seagen Inc's history began when the founders, Clay Siegall and H. Perry Fell, decided to establish a company focused on developing innovative technologies and biological solutions for fighting cancer. The company started with a small workforce and a focus on the development of antibodies against cancer cells. Over the years, Seagen has become a major player in the industry and has launched several successful drugs worldwide. Seagen Inc specializes in the development of cancer medications, including antibodies against cancer cells. The company strives to improve the effectiveness of cancer treatments and reduce the number of side effects. Its flagship products are Adcetris and Padcev, both used for the treatment of specific types of cancer. Adcetris (Brentuximab Vedotin) is an antibody-drug conjugate and the first of its kind approved worldwide for use against Hodgkin lymphomas and systemic anaplastic large cell lymphoma. It contains a special chemical that is bound to an antibody to directly attack cancer cells. Adcetris has proven to be very effective against lymphomas and is available on prescription in many countries. Padcev (Enfortumab Vedotin-ejfv) is another antibody-drug conjugate used for the treatment of bladder cancer. The drug has shown effectiveness in clinical studies and has been approved by the FDA to help patients who have no other treatment options. Padcev is being developed and marketed by Seagen in collaboration with Astellas Pharma. In addition to developing cancer medications, Seagen Inc is also involved in the research and development of technologies for autoimmune disease therapy. The company has developed a technology platform that has proven to be highly effective in the development of antibody-based therapies. This platform is used both internally and in partnerships with other pharmaceutical companies. Seagen Inc also leverages partnerships to expand its business globally and advance the development of new therapies. The company has entered into a strategic partnership with Takeda Pharmaceutical to support the development and commercialization of Adcetris. Additionally, Seagen Inc collaborates with various universities and research institutions to develop new technologies and treatment options. Overall, Seagen Inc has experienced strong growth in recent years and has become a major player in the biotech and pharmaceutical industry. The company remains committed to its mission of developing innovative technologies and solutions for fighting cancer and other chronic diseases. Seagen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seagen stock

FCF Conversion Rate (FCF/EBITDA) of Seagen is 93.47 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Seagen changed from 87.02 % to 93.47 %, representing a 7.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Seagen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Seagen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Seagen

All Key Metrics — Seagen